• If you are wondering whether Harrow's share price still reflects fair value or has already run ahead of itself, you are not alone. This article explores that question in more detail.
• Harrow recently closed at US$52.78, with returns of 4.4% over 7 days, 18.7% over 30 days, 5.8% year to date, 90.8% over 1 year and a very large gain over 5 years.
• Recent news around Harrow has kept investor attention firmly on the stock, with coverage focusing on its position in the pharmaceuticals space and how its current share price lines up against its fundamentals. This context helps explain why the market is actively reassessing what counts as a reasonable price for the business.
• On Simply Wall St's 6 point valuation checklist, Harrow scores a 5 out of 6. Below, we break down this score using several common valuation methods, followed by a broader framework for thinking about what the shares could be worth over time.

Approach 1: Harrow Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and then discounting those cash flows back to today using a required rate of return.

For Harrow, the model used here is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $75.1 million. Analyst estimates and subsequent extrapolations in this model indicate free cash flow of $416.4 million by 2030, with intermediate projections between 2026 and 2035 ranging from $81.7 million to $662.8 million, all in dollar terms.

After discounting these projected cash flows, Simply Wall St arrives at an estimated intrinsic value of about $334.27 per share. Compared with the recent share price of US$52.78, this valuation suggests the stock is 84.2% undervalued according to this DCF model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Harrow is undervalued by 84.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Harrow Price vs Sales

For companies where investors focus on revenue rather than current profits, the P/S ratio is often a useful cross check, because it compares the market value of the business with the sales it is already generating.

Higher growth expectations and lower perceived risk usually justify a higher P/S multiple, while slower growth and higher risk tend to align with a lower multiple, so context really matters when you look at the headline number.

Harrow currently trades on a P/S of 7.82x, compared with the Pharmaceuticals industry average of 4.30x and a peer average of 17.37x. Simply Wall St also calculates a proprietary “Fair Ratio” of 8.44x for Harrow, which is the P/S level suggested by a blend of factors such as earnings growth, industry, profit margin, market cap and company specific risks.

This Fair Ratio is designed to be more tailored than a simple peer or industry comparison because it adjusts for Harrow’s own growth profile, risk characteristics and business quality instead of assuming that all companies in the group deserve similar multiples.

Since Harrow’s actual P/S of 7.82x is below the Fair Ratio of 8.44x, this framework indicates that the shares may be undervalued on a sales basis.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies.

Upgrade Your Decision Making: Choose your Harrow Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Narratives let you attach a clear story about Harrow to the numbers you are seeing by linking your view on its future revenue, earnings and margins to a financial forecast, a fair value, and then a simple comparison of that fair value with the current share price. All of this is available inside the Narratives tool on Simply Wall St's Community page that millions of investors use, where each Narrative updates automatically when new news or earnings arrive. For Harrow specifically, one investor might back a higher fair value such as US$90.32 while another leans toward a lower figure like US$59.00, reflecting different views on how much market share Harrow could win and how its profitability might evolve over time.

Do you think there's more to the story for Harrow? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.